Analysts Offer Insights on Healthcare Companies: Sintx Technologies (SINT), Motus Gi Holdings (MOTS) and Valneva (VALN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sintx Technologies (SINT – Research Report), Motus Gi Holdings (MOTS – Research Report) and Valneva (VALN – Research Report) with bullish sentiments.

Sintx Technologies (SINT)

Maxim Group analyst Tate Sullivan maintained a Buy rating on Sintx Technologies yesterday and set a price target of $1.00. The company’s shares closed last Friday at $0.32, close to its 52-week low of $0.30.

According to TipRanks.com, Sullivan is a 5-star analyst with an average return of 12.0% and a 36.4% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as Natural Gas Services Group, Seanergy Maritime, and Globus Maritime.

Sintx Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.

See the top stocks recommended by analysts >>

Motus Gi Holdings (MOTS)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Motus Gi Holdings, with a price target of $11.00. The company’s shares closed last Friday at $2.45, close to its 52-week low of $2.27.

According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.1% and a 27.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, EyePoint Pharmaceuticals, and Greenwich LifeSciences.

Currently, the analyst consensus on Motus Gi Holdings is a Strong Buy with an average price target of $10.50.

Valneva (VALN)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Valneva, with a price target of $27.00. The company’s shares closed last Friday at $10.26, close to its 52-week low of $9.77.

According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -23.1% and a 24.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Valneva has an analyst consensus of Moderate Buy, with a price target consensus of $21.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SINT:

• Arbor Realty Trust Declares Preferred Stock Dividends
• Chardan Capital Remains a Buy on Rocket Pharmaceuticals (RCKT)
• Echelon Wealth Partners Reaffirms Their Buy Rating on Cognetivity Neurosciences (CGNSF)
• Intercept Pharma (ICPT) Receives a Buy from Needham
• Needham Sticks to Their Buy Rating for Zealand Pharma (ZEAL)